Reported Earlier, Kodiak Sciences Announced Treatment Of First Patients In Phase 3 GLOW2 Study Of Tarcocimab Tedromer In Diabetic Retinopathy
Reported Earlier, Kodiak Sciences Announced Treatment Of First Patients In Phase 3 GLOW2 Study Of Tarcocimab Tedromer In Diabetic Retinopathy
Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.
致力於研究、開發和商業化治療廣譜視網膜疾病的變革性療法的生物製藥公司柯迪亞克科學公司（納斯達克股票代碼：KOD）今天宣佈，在tarcocimab tedromer的隨機雙面掩蓋3期 GLOW2 研究中，首批糖尿病視網膜病變（DR）患者接受了治療。
GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in ≥ 2-step improvement in DRSS (treatment) and 89% decreased risk of developing sight-threatening complications (prevention).
GLOW2 是第二項針對糖尿病視網膜病變的tarcocimab的3期研究，在該研究中，所有接受研究性治療的患者都將在延長給藥間隔內接受tarcocimab，包括所有患者的6個月給藥。GLOW2 研究設計反映了成功的 GLOW1 研究，在該研究中，在爲期 48 周的研究期間，接受他考西單抗治療的患者在 DRSS（治療）的兩步改善中反應率提高了 29 倍，出現危及視力的併發症（預防）的風險降低了 89%。